

2026 HALF-YEAR RESULTS

Presentation for investors, analysts and media

Basel, August 19, 2026

straumanngroup

DISCLAIMER

This presentation contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Group as of the date such statements are made. Forward-looking statements are neither historical facts nor assurances of future performance. They may, but need not, be identified by words such as: "anticipate," "intend," "plan," "goal," "believe," "project," "estimate," "expect," "future," "likely," "may," "should," "will" and similar references to future periods or events. Such forward-looking statements reflect the views, beliefs, assumptions and expectations of Straumann Group or its management at the time the statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may be outside of Straumann Group's control. Such known and unknown risks, uncertainties and other factors underlying forward-looking statements may cause the actual results, performance or achievements of the Group to differ materially from those expressed or implied in this presentation. Accordingly, you should not rely on any forward-looking statements contained in this presentation. Important factors that could cause the Group's expectations regarding future results, performance or achievements to differ materially from those expressed in a forward-looking statement include, but are not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann Group's control. Should one or more of these risks, uncertainties or other factors materialize or should underlying views, beliefs, assumptions or expectations prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann Group is providing the information in this presentation as of the date it is given and does not undertake any obligation to update any statements as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities.

AGENDA

1	Performance overview	Guillaume Daniellot
2	Financial performance	Isabelle Wege
3	Strategy update	Guillaume Daniellot
4	2026 outlook	Guillaume Daniellot
5	Q&A	Guillaume Daniellot & Isabelle Wege

1

PERFORMANCE OVERVIEW

– GUILLAUME DANIELLOT, GROUP CEO –

STRONG FIRST-HALF PERFORMANCE AND CONFIRMED OUTLOOK

Growth, market share gains and margin progress

Revenue in Q2 2026

707.0 M

CHF 1.4 bn revenue in H1

Q2 organic growth in 2026

8.5%

5.9% in CHF and
7.8% organic growth in H1 or 2.3% in CHF

EBIT margin at constant
currency¹

26.9%

Core EBIT margin 25.7%
including currency impact

Digital solutions

IOS STRONG PERFORMANCE

SIRIOS X3 & software drove double-digit
revenue growth

Profitability

STRONG OPERATIONAL LEVERAGE

Manufacturing productivity, supply-chain
optimization and disciplined OPEX
management

Outlook 2026²


**CORE EBIT MARGIN EXPANSION OF
AROUND 140 TO 170 BPS¹**

High single digit organic revenue growth


5 ¹ At constant 2025 exchange rates

² Barring unforeseen events

STRONG GROWTH ACROSS REGIONS WITH VARIED MARKET DYNAMICS



REGIONAL % SHARE OF ORGANIC GROWTH



2


FINANCIAL PERFORMANCE

– ISABELLE WEGE, GROUP CFO –

GROSS PROFIT MARGIN AT 70.5% ON A HIGH LEVEL

Thanks to improved profitability despite tariffs and growth investments


in %, rounded



CORE EBIT MARGIN INCREASED TO 25.7%

EBIT margin amounting to 26.9% at constant 2025 currency exchange rates


in %, rounded



CORE NET RESULT¹ REACHED CHF 262 M


Core net result margin 19.0%

in CHF million, rounded



STRONG CASH POSITION

in CHF million, rounded



CAPITAL ALLOCATION PRIORITY ORDER DRIVES INVESTMENTS

1 REINVESTMENT IN THE BUSINESS TO DRIVE SUSTAINABLE FUTURE GROWTH

2 STRONG BALANCE SHEET TO ACCELERATE STRATEGIC PRIORITIES AND PURSUE M&A

3 MAINTAINING AND INCREASING DIVIDENDS WITH EARNINGS

3

STRATEGY UPDATE

– GUILLAUME DANIELLOT, GROUP CEO –

A LARGE MARKET WITH SIGNIFICANT ROOM TO GROW

**CHF 20 BN
MARKET
OPPORTUNITY**

**14 % MARKET
SHARE**


PERFORM

IMPLANTOLOGY



Market share

REGENERATIVES




TRANSFORM

CLEAR ALIGNER



DIGITAL EQUIPMENT



CADCAM PROSTHETICS



CONSISTENTLY GAINING MARKET SHARE

OUR GROWTH PLAYBOOK: PRODUCT LEADERSHIP × CUSTOMER EXPERIENCE

STRAUMANN IEXCEL
IMPLANT SYSTEM



CLEARCORRECT SCALLOPED
TRIMLINE ALIGNER

STRAUMANN FAST
MOLAR SOLUTION



SIRIOS X3 INTRAORAL SCANNER



STRAUMANN ACCESS CLOUD-BASED PLATFORM

INNOVATION
drives product excellence



DIGITALIZATION
enhances efficiency & clinician experience

EDUCATION

DIGITAL EFFICIENCY IS DRIVING MARKET SHARE GAINS

DOUBLE DIGIT
scanners sold

IOS PORTFOLIO – MULTI BRANDING & MULTI PRICING

Premium



3Shape
TRIOS 5/6

Mid



SIRIOS X3


Entry



SIRIOS


DOUBLE DIGIT
increase of active users

OPEN-CLOUD BASED STRAUMANN AXS PLATFORM



DOUBLE DIGIT
growth in healing abutments

STRAUMANN GROUP PRODUCT PORTFOLIO



Implant system



Abutments



Consumables

Hardware
& software



CUSTOMER EXPERIENCE LEADERSHIP DRIVES PRACTICE EFFICIENCY

FAST MOLAR WORKFLOW



Appointment



Place Fast Molar Scan Fast Molar




Appointment

Save one full patient appointment
by scanning on the day of surgery*



Appointment



Restore


TRADITIONAL WORKFLOW




Place
Healing Abutment




Remove
Healing Abutment




Place
Scanbody



Scan
Scanbody



Remove
Scanbody



Place
Healing Abutment




Restore

*Based on anecdotal clinical experiences from Straumann customers

AI-POWERED IMPLANT CONVERSION DRIVES PRACTICE GROWTH



FROM A 2D PHOTO TO A DYNAMIC 3D SIMULATION – INSTANTLY AT THE CHAIRSIDE



See it in action: [Smilecloud](https://www.smilecloud.com)



AI-enabled “YES” simulation visualizes outcomes for advanced implant cases



Builds patient confidence and supports case conversion



Connected to Straumann AXS for efficient digital case collaboration

INNOVATION AND DIGITAL WORKFLOWS EXTEND PREMIUM GROWTH



DRIVING PREMIUM LEADERSHIP

- iEXCEL drives conversions, new account wins and share gains across key geographies, representing close to 40% of Straumann premium implant volumes
- iGuide connects digital planning with guided implant treatment, improving efficiency and strengthening the premium workflow proposition

INVESTING IN CHALLENGER EXPANSION

GLOBAL



Neodent continues to scale globally through further investments into:

- Go-to-market capabilities in key geographies
- Education to accelerate customer adoption
- Capacity expansion in Curitiba

REGIONAL




Medentika builds on its leading MPS abutment system, compatible with all major implant systems, and a locally developed implant line for China



Anthogyr expands its reach in EMEA with the versatile Axiom X3 implant system, combining clinical differentiation with treatment simplicity

CHINA REMAINS A LARGE, UNDERPENETRATED IMPLANT MARKET

Global implant penetration per 10'000 adult inhabitants



«Implant penetration in China remains well below mature-market levels, creating substantial headroom for long-term volume growth.»

Straumann Group estimates, assumption that 100% of adult population can afford implant treatment

OUR GLOBAL GROWTH PLAYBOOK, ADAPTED TO WIN IN CHINA



Implant market segments in China



Challenger


Premium

Our winning strategy in China

- **Multi-brand, multi-price-point portfolio**
Serving distinct customer needs from premium to challenger
- **Local manufacturing**
lower cost base, better supply resilience
- **Local partners and education**
Broader market access, clinician adoption and customer trust

CLEARCORRECT TRANSFORMATION PROGRESSING FAST

clearcorrect
A Straumann Group Brand



NEW CLEARCORRECT VALUE PROPOSITION GAINING TRACTION WITH CUSTOMERS

- New digital features are driving strong GP adoption, accelerating active case growth and supporting market share gains
- AI-enabled tools, especially Case Assessment, help GPs treat more patients and start more active cases
- Consistent turnaround times strengthen the ClearCorrect brand with GPs, support further growth and keep us on track for break-even by end-2027

ONGOING INVESTMENTS TO FUEL FUTURE GROWTH



Innovation & Digital Transformation



Operations & Go-To-Market Initiatives



People & Culture



4

2026 OUTLOOK

– GUILLAUME DANIELLOT, GROUP CEO –

UPGRADED OUTLOOK 2026¹ – CONFIRMED

- High-single digit organic revenue growth
- 140 to 170 basis points improvement of the core EBIT margin at constant 2025 exchange rates

- Significant growth opportunities in a CHF 20bn+ addressable market with strong fundamentals
- Proven business model with strong market positions amid continued volatility
- Strong innovation pipeline and transformation initiatives fueling future growth

ANY QUESTIONS?



CALENDAR OF UPCOMING EVENT


2026	Event	Location
20-21 Aug	Octavian Roadshow	Zurich & Geneva
1 Sep	Octavian HC Field Trip	Basel
2-3 Sep	Bernstein Roadshow	Copenhagen & Stockholm
2 Sep	BNP Paribas Bus Tour	Basel
9 Sep	Goldman Sachs European MedTech Conference	London
22-23 Sep	Bank of America Global Healthcare Conference	London
25 Sep	Barclays EU MedTech& Life Sciences Investor Trip	Virtual
30 Sep-27 Oct	Quiet period	
28 Oct	Third-quarter 2026 results	Webcast

A high-angle photograph of a surfer with blonde hair, wearing a black wetsuit, riding a wave. The surfer is positioned on the right side of the frame, leaning back on their surfboard. The wave is a vibrant blue-green color with white foam at the crest. The background is a bright, hazy sky. The text "THANK YOU." is overlaid on the left side of the image.

THANK YOU.

REVENUE DEVELOPMENT HALF-YEAR 2026

(in CHF million, rounded)



CORE RESULTS RECONCILIATION

H1, 2026 (in CHF 1 000)	IFRS	M&A	Impairments	Legal cases	Pension plan settlements	Other	CORE
Revenue	1 379 469						1 379 469
Cost of goods sold	(386 854)	60				(20 816)	(407 611)
Gross profit	992 615	60				(20 816)	971 858
Other income	8 194						8 194
Distribution expense	(268 111)	2 949					(265 162)
Administrative expense	(382 138)	5 050		18 000	(991)		(360 079)
Operating profit	350 560	8 059		18 000	(991)	(20 816)	354 811
Finance income	43 032	(4 977)				(741)	37 315
Finance expense	(73 787)	10 845					(62 942)
Share of result of associates	(6 483)						(6 483)
Profit before income tax	313 321	13 928		18 000	(991)	(21 557)	322 701
Income tax expense	(62 641)	(1 453)		(2 493)	137	5 734	(60 716)
NET PROFIT FROM CONTINUING OPERATIONS	250 680	12 475		15 507	(854)	(15 823)	261 985
Loss from discontinued operations, net of tax	0						0
NET PROFIT	250 680	12 475		15 507	(854)	(15 823)	261 985
Attributable to:							
Shareholders of the parent company	249 703	12 434		15 507	(854)	(15 823)	260 967
Non-controlling interests	977	41					1 018
Basic earnings per share (in CHF)	1.57						1.64
Diluted earnings per share (in CHF)	1.57						1.64
Basic earnings per share continuing operations (in CHF)	1.57						1.64
Diluted earnings per share continuing operations (in CHF)	1.57						1.64
Operating profit	350 560	8 059		18 000	(991)	(20 816)	354 811
Depreciation, amortization and impairment	84 779	(8 059)					76 720
EBITDA	435 339			18 000	(991)	(20 816)	431 531

HALF-YEAR 2026 CORE FINANCIALS AT A GLANCE

Core net profit at 19.0%

	HY 2026 ¹	% of Revenue	Change in % CER ²	Margin Change CER ²
REVENUE	1 379		+7.8%	
COGS	-408	29.5%		
GROSS PROFIT	972	70.5%	+6.9%	-50 bps
Operating expenses	-625	45.3%		
Other Result	8	0.6%		
EBIT	355	25.7%	+11.9%	+95 bps
EBIT Margin at 2025³		26.9%		+101 bps
Financial result	-26	1.9%		
Associates	-6	0.5%		
Income tax	-61	4.4%		
NET PROFIT (from continuing operations)	262	19.0%	+15.7%	+130bps
Loss from discontinued operations	0			
NET PROFIT	262	19.0%	+16.1%	+136 bps
Basic EPS⁴	1.64			


HALF-YEAR 2026 IFRS FINANCIALS AT A GLANCE

IFRS net profit at 18.2%


	HY 2026 ¹	% of Revenue	Change in % CER ²	Margin Change CER ²
REVENUE	1 379		+7.8%	
COGS	-387	28.0%		
GROSS PROFIT	993	72.0%	+9.6%	+118bps
Operating expenses	-650	47.1%		
Other Result	8	0.6%		
EBIT	351	25.4%	+21.3%	+282 bps
Financial result	-31	2.2%		
Associates	-6	0.5%		
Income tax	-63	4.5%		
NET PROFIT (from continuing operations)	251	18.2%	+25.8%	+260 bps
Loss from discontinued operations	0			
NET PROFIT	251	18.2%	+26.3%	+266 bps
Basic EPS	1.57			

CURRENCY EXPOSURE


Revenue breakdown H1 2026



Total cost breakdown H1 2026



Exchange rates development 2024 – 2026



Average exchange rates (rounded)					Closing	FX sensitivity (+/- 10%) on HY	
		2024	2025	Jun 2026	Jun 2026	Revenue	EBIT
1	EURCHF	0.951	0.936	0.920	0.922	+/- 36m	+/- 13m
1	USDCHF	0.879	0.834	0.789	0.810	+/- 35m	+/- 13m
1	BRLCHF	0.164	0.149	0.152	0.156	+/- 9m	+/- 5m
1	CNYCHF	0.122	0.116	0.115	0.119	+/- 21m	+/- 15m